Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Assets (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Current Assets data on record, last reported at $101.0 million in Q3 2025.

  • For Q3 2025, Current Assets rose 17.63% year-over-year to $101.0 million; the TTM value through Sep 2025 reached $101.0 million, up 17.63%, while the annual FY2024 figure was $163.4 million, 221.27% up from the prior year.
  • Current Assets reached $101.0 million in Q3 2025 per CAPR's latest filing, down from $124.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $163.4 million in Q4 2024 and bottomed at $29.5 million in Q3 2023.
  • Average Current Assets over 5 years is $64.2 million, with a median of $46.6 million recorded in 2023.
  • Peak YoY movement for Current Assets: plummeted 37.84% in 2023, then surged 304.73% in 2025.
  • A 5-year view of Current Assets shows it stood at $36.4 million in 2021, then grew by 17.71% to $42.9 million in 2022, then increased by 18.58% to $50.9 million in 2023, then surged by 221.27% to $163.4 million in 2024, then plummeted by 38.21% to $101.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $101.0 million in Q3 2025, $124.1 million in Q2 2025, and $146.3 million in Q1 2025.